The Janssen Pharmaceutical Companies of Johnson & Johnson announced unblinding of the phase III TITAN study evaluating Erleada (apalutamide) plus androgen deprivation therapy in the treatment of patients with metastatic castration-sensitive prostate cancer.
Findings from a pilot study at the University of Missouri School of Medicine show antioxidants such as alpha-lipoic acid may show promise working in tandem with temozolomide to further slow brain tumor growth in glioblastoma.
Finasteride, a generic hormone-blocking drug, was found to reduce the risk of prostate cancer by 25 percent in the landmark Prostate Cancer Prevention Trial.
The Addario Lung Cancer Medical Institute and researchers from the Dana-Farber Cancer Institute are launching a novel nationwide study to understand why treatment resistance develops in a specific group of lung cancer patients.
Note: The Cancer Letter has previously published information regarding this and can be found here.
Stephen Meltzer, a professor of medicine and oncology at the Johns Hopkins University School of Medicine, along with a team of researchers, clinicians and biomedical engineers have created a test—the “EsophaCap”—that uses specific genetic biomarkers to detect dangerous changes in the cells that line the inside of the esophagus. The paper was published in Clinical Cancer Research.
AbbVie announced an update on the phase III RESOLVE trial (PCYC-1137) of ibrutinib (Imbruvica) in combination with chemotherapy agents nab-paclitaxel and gemcitabine versus placebo in combination with these chemotherapy agents in patients with metastatic pancreatic adenocarcinoma.
Merck announced the first presentation of results from KEYNOTE-181, a phase III trial investigating Keytruda, an anti-PD-1 therapy, as monotherapy for the second-line treatment of advanced or metastatic esophageal or esophagogastric junction carcinoma.
Array BioPharma Inc. announced updated safety and efficacy results, including mature overall survival, from the safety lead-in of the phase III BEACON CRC trial evaluating the triplet combination of Braftovi (encorafenib), a BRAF inhibitor, Mektovi (binimetinib), a MEK inhibitor and Erbitux (cetuximab), an anti-EGFR antibody, in patients with BRAFV600E-mutant metastatic colorectal cancer.
A global resource that includes data on thousands of inherited variants in the BRCA1 and BRCA2 genes is available to the public. The BRCA Exchange was created through the BRCA Challenge, a long-term demonstration project initiated by the Global Alliance for Genomics and Health to enhance sharing of BRCA1 and BRCA2 data.